doi: 10.3389/fevo.2023.1293585 Received 13 September 2023 Accepted 23 November 2023 Published 03 January 2024 Volume 11 - 2023 Edited by Ernesto Mollo, National Research Council (CNR), Italy Reviewed by Olivier P
Ly C, Yockell-Lelievre J, Ferraro ZM, Arnason JT, Ferrier J, Gruslin A
Our results show that ESOL-based models to be slightly inferior to deep-learning and boosted-tree methods on a variety of benchmarks
However, a multifaceted approach involving advanced pharmaceutical interventions, gene therapy, in silico modeling, nanotechnology, stem cell therapy, and bilirubin-binding agents holds promise for the management of bilirubin-related disorders in the future
Athletes subject to drug testing should not use ipamorelin